

Supporting Table 1 Subgroups of Chemotherapy Regimens with Different Outcomes In Chemotherapy-Induced Leukopenia Between Two Groups

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
Chemotherapy regimens 1						
Mild	121	10	<0.0001	142	58	<0.0001
Severe	33	25		37	115	
Chemotherapy regimens 2						
Mild	35	22	0.000025	54	24	0.000006
Severe	7	32		9	28	
Chemotherapy regimens 3						
Mild	52	25	0.000153	65	56	0.080
Severe	120	158		164	204	
Chemotherapy regimens 4						
Mild	53	28	0.000074	67	31	0.000034
Severe	32	59		39	61	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression. **Chemotherapy:**

- 1 The chemotherapy contains AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF (Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil).
- 2 The chemotherapy contains TC (Paclitaxel or Docetaxel, Cyclophosphamide), T (Paclitaxel or Docetaxel).
- 3 The chemotherapy contains anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (Paclitaxel or Docetaxel, Cyclophosphamide, Adriamycin or Epirubicin); TA/TE (Paclitaxel or Docetaxel, Adriamycin or Epirubicin).
- 4 The chemotherapy contains anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF (Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil), followed with T or TH (Paclitaxel or Docetaxel, herceptin).

Supporting Table 2 Subgroups of Chemotherapy Regimens with Different Outcomes In Chemotherapy-Induced Neutropenia Between Two Groups

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
Chemotherapy regimens 1						
Mild	61	11	0.368	72	59	0.235
Severe	93	24		107	114	
Chemotherapy regimens 2						
Mild	27	17	0.001	44	15	0.000012
Severe	15	37		19	37	
Chemotherapy regimens 3						
Mild	21	18	0.475	26	26	0.628
Severe	151	165		203	234	
Chemotherapy regimens 4						
Mild	17	18	0.911	21	22	0.485
Severe	68	69		85	70	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression. **Chemotherapy:**

- 1 The chemotherapy contains AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF(Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil).
- 2 The chemotherapy contains TC (Paclitaxel or Docetaxel, Cyclophosphamide), T (Paclitaxel or Docetaxel).
- 3 The chemotherapy contains anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (Paclitaxel or Docetaxel, Cyclophosphamide, Adriamycin or Epirubicin); TA/TE (Paclitaxel or Docetaxel , Adriamycin or Epirubicin).
- 4 The chemotherapy contains anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF (Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil), followed with T or TH(Paclitaxel or Docetaxel, herceptin).

Supporting Table 3 Subgroups of Chemotherapy Regimens with Different Outcomes In Chemotherapy-Induced FN Between Two Groups

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
Chemotherapy regimens 1						
Mild	153	30	0.000295	178	144	<0.0001
Severe	1	5		1	29	
Chemotherapy regimens 2						
Mild	42	45	0.004	63	45	0.003053
Severe	0	9		0	7	
Chemotherapy regimens 3						
Mild	150	110	<0.0001	200	179	0.000001
Severe	22	73		29	81	
Chemotherapy regimens 4						
Mild	83	69	0.000176	104	71	<0.0001
Severe	2	18		2	21	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression. **Chemotherapy:**

- 1 The chemotherapy contains AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF (Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil).
- 2 The chemotherapy contains TC (Paclitaxel or Docetaxel, Cyclophosphamide), T (Paclitaxel or Docetaxel).
- 3 The chemotherapy contains anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (Paclitaxel or Docetaxel, Cyclophosphamide, Adriamycin or Epirubicin); TA/TE (Paclitaxel or Docetaxel, Adriamycin or Epirubicin).
- 4 The chemotherapy contains anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or Epirubicin, Cyclophosphamide), CAF/CEF (Adriamycin or Epirubicin, Cyclophosphamide, 5-Fluorouracil), followed with T or TH (Paclitaxel or Docetaxel, herceptin).

**Supporting Table 4 Subgroups of Tumor Stage with Different Outcomes In
Chemotherapy-Induced Leukopenia Between Two Groups**

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
TNM stage I						
Mild	108	44	0.000003	141	63	<0.0001
Severe	56	73		74	101	
TNM stage II						
Mild	136	32	<0.0001	169	83	<0.0001
Severe	83	157		106	250	
TNM stage III&IV						
Mild	17	9	0.326	18	23	0.227
Severe	53	44		69	57	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression.

**Supporting Table 5 Subgroups of Tumor Stage with Different Outcomes In
Chemotherapy-Induced Neutropenia Between Two Groups**

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
TNM stage I						
Mild	55	33	0.342	76	53	0.537
Severe	109	84		139	111	
TNM stage II						
Mild	66	24	0.000023	81	54	0.000093
Severe	153	165		194	279	
TNM stage III&IV						
Mild	5	7	0.262	6	15	0.021
Severe	65	46		81	65	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression.

**Supporting Table 6 Subgroups of Tumor Stage with
Different Outcomes In Chemotherapy-Induced FN Between Two Groups**

Outcomes	Before Propensity Matching			After Propensity Matching		
	Group1 (n)	Group2 (n)	P	Group1 (n)	Group2 (n)	P
TNM stage I						
Mild	154	90	0.000033	199	130	0.000152
Severe	10	27		16	34	
TNM stage II						
Mild	212	127	<0.0001	268	246	<0.0001
Severe	7	62		7	87	
TNM stage III&IV						
Mild	62	37	0.009	78	63	0.052
Severe	8	16		9	17	

Mild: Grade I and II myelosuppression. **Severe:** Grade III and IV myelosuppression.

Supporting Table 7 The Toxicity of TCM

Variables	Before Propensity Matching			After Propensity Matching		
	Group1 (n=453)	Group2 (n=359)	P	Group1 (n=577)	Group2 (n=577)	P
Renal damage						
BUN (mmol /L)						
2.14-7.14	453	359		577	577	
> 7.14	0	0		0	0	
CR (umol /L)						
45-84	453	359		577	577	
> 84	0	0		0	0	
Hepatic dysfunction						
ALT (IU/L)						
≤40	382	257	0.000842	487	446	0.004167
>40	71	102		90	131	
AST (IU/L)						
≤40	394	281	<0.0001	499	483	<0.0001
>40	59	78		78	94	

ALT, alanine aminotransferase; AST, aspartase transferase. BUN, blood urea nitrogen creatinine; CR, creatinine.